Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

Purpose Infliximab, a monoclonal antibody, is approved for the treatment of inflammatory diseases at doses that depend on the patient disease population. It was the aim of this study to evaluate its population pharmacokinetics in patients with moderately to severely active ulcerative colitis and cha...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical pharmacology 2009-12, Vol.65 (12), p.1211-1228
Hauptverfasser:	Fasanmade, Adedigbo A, Adedokun, Omoniyi J, Ford, Joyce, Hernandez, Danika, Johanns, Jewel, Hu, Chuanpu, Davis, Hugh M, Zhou, Honghui
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anti-Inflammatory Agents - pharmacokinetics Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Bayes Theorem Biological and medical sciences Biomedical and Life Sciences Biomedicine Colitis, Ulcerative - drug therapy Colitis, Ulcerative - metabolism Double-Blind Method Female Gastroenterology. Liver. Pancreas. Abdomen Humans Inflammatory bowel disease Infliximab Male Medical sciences Models, Biological Other diseases. Semiology Pharmacokinetics and Disposition Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Placebos Prescription drugs Serum Albumin - metabolism Severity of Illness Index Sex Factors Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!